Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Crombez

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
The Journal of Pediatrics|July 20, 2005
Pitfalls in newborn screeningEric Crombez, Richard Koch, Stephen Cederbaum
American Journal of Hematology|April 24, 2015
Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher diseaseAri Zimran, Nan Wang, Carol Ogg, et al.
Journal of Child Neurology|July 9, 2016
Metachromatic Leukodystrophy: An Assessment of Disease BurdenFlorian S Eichler, Timothy M Cox, Eric Crombez, et al.
Blood Advances|April 8, 2025
Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studiesSteven Pipe, Allen Poma, Anita Rajasekhar, et al.
Molecular Genetics and Metabolism|June 6, 2015
Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imigluceraseLaurie Smith, William Rhead, Joel Charrow, et al.
American Journal of Hematology|March 18, 2015
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher diseaseDeborah Elstein, Atul Mehta, Derralynn A Hughes, et al.
American Journal of Hematology|February 7, 2013
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 studyDerlis E Gonzalez, Hadhami Ben Turkia, Elena A Lukina, et al.
American Journal of Hematology|March 25, 2015
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trialsDerralynn A Hughes, Derlis E Gonzalez, Elena A Lukina, et al.
American Journal of Medical Genetics. Part A|October 22, 2008
Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuriaPhillip Lee, Eileen P Treacy, Eric Crombez, et al.
American Journal of Hematology|February 13, 2013
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher diseaseHadhami Ben Turkia, Derlis E Gonzalez, Norman W Barton, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Journal of Pediatrics|July 20, 2005
Pitfalls in newborn screeningEric Crombez, Richard Koch, Stephen Cederbaum
American Journal of Hematology|April 24, 2015
Seven-year safety and efficacy with velaglucerase alfa for treatment-naïve adult patients with type 1 Gaucher diseaseAri Zimran, Nan Wang, Carol Ogg, et al.
Journal of Child Neurology|July 9, 2016
Metachromatic Leukodystrophy: An Assessment of Disease BurdenFlorian S Eichler, Timothy M Cox, Eric Crombez, et al.
Blood Advances|April 8, 2025
Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studiesSteven Pipe, Allen Poma, Anita Rajasekhar, et al.
Molecular Genetics and Metabolism|June 6, 2015
Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imigluceraseLaurie Smith, William Rhead, Joel Charrow, et al.
American Journal of Hematology|March 18, 2015
Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher diseaseDeborah Elstein, Atul Mehta, Derralynn A Hughes, et al.
American Journal of Hematology|February 7, 2013
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 studyDerlis E Gonzalez, Hadhami Ben Turkia, Elena A Lukina, et al.
American Journal of Hematology|March 25, 2015
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trialsDerralynn A Hughes, Derlis E Gonzalez, Elena A Lukina, et al.
American Journal of Medical Genetics. Part A|October 22, 2008
Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuriaPhillip Lee, Eileen P Treacy, Eric Crombez, et al.
American Journal of Hematology|February 13, 2013
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher diseaseHadhami Ben Turkia, Derlis E Gonzalez, Norman W Barton, et al.
Pageof 2